

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-19. (Canceled)

20. (Currently amended) A method for decreasing expression of livin in a cell, comprising (a) synthesizing ~~Preparing~~ siRNA from a nucleic acid comprising any one of SEQ ID NOs: 1-8 containing a sequence selected from the group consisting of SEQ ID NO:1, a fragment or derivative thereof, SEQ ID NO:2, a fragment or derivative thereof, SEQ ID NO:6, a fragment or derivative thereof, and SEQ ID NO: 7, a fragment or derivative thereof; and (b) administering said siRNA to said cell. ~~therapy-resistant tumor cells.~~

21. (Currently amended) The method of claim 20, wherein said nucleic acid has a length of ~~15 to 25 nucleotides, preferably 18 to 22 nucleotides and most preferably 19-21~~ nucleotides.

22. (Currently amended) The method of claim 20, wherein said cell is a ~~the siRNA is delivered into a therapy-resistant tumor cell.~~

23. (Currently amended) The method of claim ~~[[22]]~~ 20, wherein said administration ~~the delivery~~ is done by using liposomes or hydrodynamic injection.

24. (Currently amended) A method for sensitizing a livin-expressing ~~therapy-resistant tumor cell~~ cells for apoptosis comprising (a) synthesizing ~~preparing~~ siRNA from a nucleic acid comprising any one of SEQ ID NOs: 1-8 containing the sequence of SEQ ID NO:1, a fragment or derivative thereof; or SEQ ID NO:2, a fragment or derivative thereof; and (b) administering said siRNA to said ~~therapy-resistant tumor cell~~ cells; wherein said siRNA decreases livin expression in said tumor cell.

25. (Currently amended) The method of claim 24, wherein said nucleic acid has a length of ~~15 to 25 nucleotides, preferably 18 to 22 nucleotides and most preferably 19-21~~ nucleotides.

26. (Currently amended) The method of claim 24, wherein the siRNA is ~~delivered~~ administered into a therapy-resistant tumor cell.

27. (Currently amended) The method of claim 26, wherein the ~~delivery~~ administration is done by using liposomes or hydrodynamic injection.

28-38 (Canceled).

39. (Currently amended) The method of claim ~~[[38]]~~ 24, wherein the siRNA is administered in combination with radiation therapy.

40. (Currently amended) The method of claim ~~[[38]]~~ 24, wherein the siRNA is administered in combination with an active compound which is selected from the group consisting of cytostatic compounds, death receptor ligands, antibodies to death receptors and negative regulators of anti-apoptotic proteins.

41. (Currently amended) The method of claim ~~[[38]]~~ 24, wherein ~~the therapy-resistant~~ said tumor cell is selected from the group consisting of neuroblastoma, intestine carcinoma preferably rectum carcinoma, colon carcinoma, familial adenomatous polyposis carcinoma and hereditary non-polyposis colorectal cancer, esophageal carcinoma, labial carcinoma, larynx carcinoma, hypopharynx carcinoma, tongue carcinoma, salivary gland carcinoma, gastric carcinoma, adenocarcinoma, medullary thyroid carcinoma, papillary thyroid carcinoma, follicular thyroid carcinoma, anaplastic thyroid carcinoma, renal carcinoma, kidney parenchyma carcinoma, ovarian carcinoma, ~~cervix~~ cervical carcinoma, uterine corpus carcinoma, endometrium carcinoma, chorion carcinoma, pancreatic carcinoma, prostate carcinoma, testis carcinoma, breast carcinoma, urinary carcinoma, melanoma, brain tumors preferably glioblastoma, astrocytoma, meningioma, medulloblastoma and peripheral neuroectodermal tumors, Hodgkin lymphoma, non-Hodgkin lymphoma, Burkitt lymphoma, acute lymphatic leukemia (ALL), chronic lymphatic leukemia (CLL), acute myeloid leukemia

(AML), chronic myeloid leukemia (CML), adult T-cell leukemia lymphoma, hepatocellular carcinoma, gall bladder carcinoma, bronchial carcinoma, small cell lung carcinoma, non-small cell lung carcinoma, multiple myeloma, basalioma, teratoma, retinoblastoma, choroidea melanoma, seminoma, rhabdomyosarcoma, craniopharyngeoma, osteosarcoma, chondrosarcoma, myosarcoma, liposarcoma, fibrosarcoma, Ewing sarcoma and plasmocytoma.

42. (Currently amended) The method of claim [[38]] 24, wherein ~~the therapy-resistant~~ said tumor cell is cervical carcinoma or melanoma.

43. (Currently amended) A medicament for the treatment of therapy-resistant tumors comprising a siRNA containing the sequence of SEQ ID NOs:1, 2, 3, 4, 6, 7, 8 or 9, a pharmaceutically-acceptable carrier and, optionally, an active compound.